Products
Alethia is currently focusing on cancer-associated epithelial-to-mesenchymal transition with its AB-16B5 monoclonal antibody, a clinical stage EMT inhibitor to prevent chemotherapy resistance and metastatic tumour invasion
AB-16B5 – inhibition of EMT
- Alethia is developing an inhibitor of EMT for the treatment of invasive carcinomas. AB-16B5 is a humanized IgG2 antibody against an EMT-inducing form of secreted clusterin (sCLU). AB-16B5 very efficiently blocks EMT and pre-clinical data indicate that animals xenografted with various carcinoma cells show an increase of response to standard of care chemotherapy as well as a reduction of invasion. Read more about AB-16B5
News
- May 21, 2020 Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5 MONTREAL, May 21, 2020 – Alethia Biotherapeutics announced today that the U.S. Food and Drug Administration has cleared its Phase 2 Investigational new drug (IND) application for AB-16B5, a potent inhibitor of the epithelial to mesenchymal transition (EMT).This allows the ...
Events
- May 31 – June 3, 2024 Alethia Biotherapeutics to present at the Annual ASCO Meeting at McCormick Place · Chicago, IL, USA. Dr. Normand Blais, Dr. Mario Filion, Dr. Jacques Jolivet and Dr. Julie Laurin will present : “A Phase II Trial to Evaluate the Epithelial-to-Mesenchymal (EMT) Inhibitor Sotevtamab Combined with Docetaxel in Patients With Metastatic Non Small Cell Lung Cancer Following Failure of ...